The Oncology Institute, Inc. TOI Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s debt issuance cost amortization?
- The Oncology Institute, Inc. (TOI) reported debt issuance cost amortization of $1.21M in Q1 2026.
- How has The Oncology Institute, Inc.'s debt issuance cost amortization changed year-over-year?
- The Oncology Institute, Inc.'s debt issuance cost amortization decreased by 75.2% year-over-year, from $4.87M to $1.21M.
- What is the long-term trend for The Oncology Institute, Inc.'s debt issuance cost amortization?
- Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s debt issuance cost amortization has grown at a 254.6% compound annual growth rate (CAGR), from $53K to $8.38M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).